Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci

被引:13
作者
Trautmann, M
Ruhnke, M
Borner, K
Wagner, J
Koeppe, P
机构
[1] KLINIKUM RUDOLF VIRCHOW, DEPT INTERNAL MED, BERLIN, GERMANY
[2] KLINIKUM BENJAMIN FRANKLIN, INST CLIN CHEM & CLIN BIOCHEM, BERLIN, GERMANY
[3] KLINIKUM BENJAMIN FRANKLIN, INST MED MICROBIOL, BERLIN, GERMANY
[4] KLINIKUM BENJAMIN FRANKLIN, INST MED PHYS & LASER MED, BERLIN, GERMANY
关键词
D O I
10.1128/AAC.40.3.776
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Sparfloxacin, a new fluorinated quinolone, exhibits higher in vitro activity against pneumococci than do ciprofloxacin and ofloxacin. Since up to 30% of cases of pneumococcal pneumonia are associated with bacteremia, and since an increasing percentage of pneumococci are resistant against penicillin, we studied the serum bactericidal activity of sparfloxacin against pneumococci in eight healthy, middle-aged volunteers. Pharmacokinetics in serum and urine after a 400-mg oral dose of sparfloxacin were comparable to those described by other authors. Inhibitory and bactericidal activities in serum were measured for four pneumococcal isolates representing penicillin-susceptible (one isolate), intermediately resistant (two isolates), and highly resistant (one isolate) strains. Geometric mean inhibitory titers ranged between 1:2.4 and 1:6.3 and bactericidal titers ranged between 1:1.3 and 1:3.6 during a time period of 1 to 6 h after drug intake. Although such titers were not sufficient to predict a clinical response based on previous pharmacodynamic studies using quinolone antibiotics, data obtained with volunteers may only partially reflect the clinical situation in which a rise of humoral antibodies directed against pneumococcal antigens may help to reinforce the bactericidal action of the antibiotic.
引用
收藏
页码:776 / 779
页数:4
相关论文
共 40 条
[1]  
AUBIER M, 1994, 6 INT C INF DIS PRAG
[2]   PROSPECTIVE-STUDY ON THE ETIOLOGY OF COMMUNITY-ACQUIRED PNEUMONIA IN CHILDREN AND ADULTS IN SPAIN [J].
AUSINA, V ;
COLL, P ;
SAMBEAT, M ;
PUIG, I ;
CONDOM, MJ ;
LUQUIN, M ;
BALLESTER, F ;
PRATS, G .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1988, 7 (03) :343-347
[3]   CLINICAL OUTCOME OF ACUTE OTITIS-MEDIA CAUSED BY PNEUMOCOCCI WITH DECREASED SUSCEPTIBILITY TO PENICILLIN [J].
BARRY, B ;
GEHANNO, P ;
BLUMEN, M ;
BOUCOT, I .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1994, 26 (04) :446-452
[4]   COMPARATIVE-STUDY WITH ENOXACIN AND NETILMICIN IN A PHARMACODYNAMIC MODEL TO DETERMINE IMPORTANCE OF RATIO OF ANTIBIOTIC PEAK CONCENTRATION TO MIC FOR BACTERICIDAL ACTIVITY AND EMERGENCE OF RESISTANCE [J].
BLASER, J ;
STONE, BB ;
GRONER, MC ;
ZINNER, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (07) :1054-1060
[5]   DETERMINATION OF SPARFLOXACIN IN SERUM AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
BORNER, K ;
BORNER, E ;
LODE, H .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1992, 579 (02) :285-289
[6]   INVITRO ACTIVITY OF SPARFLOXACIN COMPARED WITH THOSE OF 5 OTHER QUINOLONES [J].
CANTON, E ;
PEMAN, J ;
JIMENEZ, MT ;
RAMON, MS ;
GOBERNADO, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (03) :558-565
[7]   INVITRO ACTIVITY OF SPARFLOXACIN [J].
CHIN, NX ;
GU, JW ;
YU, KW ;
ZHANG, YX ;
NEU, HC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (03) :567-571
[8]   COMPARATIVE CROSSOVER ASSESSMENT OF SERUM BACTERICIDAL ACTIVITY AND PHARMACOKINETICS OF CIPROFLOXACIN AND OFLOXACIN [J].
ECHOLS, R ;
WEINSTEIN, MP ;
OKEEFE, B ;
SHAH, A ;
HELLER, AH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1994, 33 (01) :111-118
[9]   PHARMACODYNAMICS OF INTRAVENOUS CIPROFLOXACIN IN SERIOUSLY ILL-PATIENTS [J].
FORREST, A ;
NIX, DE ;
BALLOW, CH ;
GOSS, TF ;
BIRMINGHAM, MC ;
SCHENTAG, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :1073-1081
[10]  
FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377, DOI 10.1056/NEJM199408113310607